Iodine-131-labeled monoiodohypericin (131I-Hyp) is a necrosis avid compound used as a
complementary anticancer agent. Herein, the biodistribution in rats with re-perfused partial …

Purpose To study whether formulation influences biodistribution, necrosis avidity and
tumoricidal effects of the radioiodinated hypericin, a necrosis avid agent for a dual-targeting …

Cancers are often with spontaneous or therapeutic necrosis that could be utilized as a
generic target for developing new treatments. The purpose of this study was to investigate …

Objectives: To study the effect of co-injecting unlabelled hypericin (Hyp) on biodistribution,
necrosis uptake and tumour retention of iodine-123 or iodine-131 labelled hypericin …

Objectives: The present animal experiments were conducted to evaluate radioiodinated
Hypericin (Hyp) for its regional distribution as well as theranostic potentials. Materials and …

Aim: Hypericin (Hyp) and its radio-derivatives have been investigated in animal models with
ischemic heart diseases and malignancies for diagnostic and therapeutic purposes. Before …

Hypericin is a necrosis avid agent useful for nuclear imaging and tumor therapy.
Protohypericin, with a similar structure to hypericin except poorer planarity, is the precursor …

Hypericin (Hyp) is newly recognized as a necrosis avid agent, but its poor solubility imposes
a great hindrance in clinical application. The aim of this paper was to explore sodium …

Purpose Hypericin (HYP) has been found avid to necrosis in small animal studies. We
sought to evaluate the tissue distribution of 131 I-HYP in a large animal model and to …

We sought to reduce the radioactive intestinal waste after intravenous injection of necrosis
avid iodine-131-labeled hypericin in dual-targeting anticancer radiotherapy and to study its …